Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00114920|
Recruitment Status : Completed
First Posted : June 21, 2005
Last Update Posted : February 19, 2007
The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks.
A second purpose is to evaluate the safety of the drug.
|Condition or disease||Intervention/treatment||Phase|
|Warts||Drug: Resiquimod||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||88 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults|
|Study Start Date :||March 2004|
- Clearance of treated common wart(s)
- Partial clearance of treated common wart(s)
- Wart recurrence
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00114920
|United States, Indiana|
|Evansville, Indiana, United States, 47713|